Immunocore Holdings plc (NASDAQ:IMCR) Powers Near-Term Upside On KIMMTRAK Momentum

Commercial traction for KIMMTRAK and pipeline readouts create a bullish technical setup, while fundamentals show rapid revenue expansion alongside continued operating losses and ample liquidity. Near-term price action should track momentum indicators against a measured pullback risk signal.

Recent News

On August 6, 2026 Immunocore reported second-quarter financial results and provided a business update including commercial metrics for KIMMTRAK and pipeline progress; the company had announced on May 30, 2026 that it would report Q2 results on August 6; Immunocore also announced upcoming five‑year overall‑survival data presentations for KIMMTRAK at scientific meetings.

Technical Analysis

Directional indicators show a trending market: ADX at 29.6 indicates a strong trend environment. DI+ at 24.36 increasing signals directional strength to the upside, while DI– at 10.61 decreasing reinforces bullish directional bias for price movement.

MACD reads 0.99 with the signal at 0.81 and an increasing MACD_trend; MACD currently sits above its signal line, which constitutes a bullish momentum confirmation for near‑term price continuation.

MRO sits at 33.63 with a dip & reversal pattern; because MRO is positive, the price currently sits above the model target and bears potential for a corrective move despite the recent bullish reversal in the oscillator.

RSI at 59.94 and rising indicates healthy buying pressure without reaching overbought territory; that supports continuation while leaving room for additional upside before technical exhaustion near the 70 threshold.

Price trades above the short and long moving averages: close $37.12 versus the 20‑day average $35.54, 50‑day $33.40 and 200‑day $32.72, and the 12‑day EMA at $36.03 shows an increasing short‑term trend. Ichimoku components (Tenkan $35.36, Kijun $34.77, Senkou span A $32.35) align with price above cloud support, reinforcing trend bias. Bollinger band width remains moderate (20‑day stdev $1.47) and the upper band near $37.01–$38.48 marks near-term resistance; a confirmed breach toward the 52‑week high $40.72 would extend momentum signals.

Volume currently lags short‑ and medium‑term averages (daily volume 255,158 vs. 10‑day avg 388,618 and 50‑/200‑day averages higher), suggesting moves have proceeded with below‑average participation and warrant watching for a pickup in volume to validate directional extensions. Beta measures low to moderate volatility (42‑day -0.32, 52‑week 0.63), implying price moves may decouple from broader market swings.

 


Fundamental Analysis

Revenue expanded meaningfully: total revenue $115.927M with YoY revenue growth of 99.38% and QoQ revenue growth of 3.12%, reflecting rapid top‑line acceleration tied to product commercialization. Gross margin at 99.06% indicates very high product gross profitability and strong unit economics for reported revenue streams.

Profitability metrics remain negative on the operating line: operating margin -2.58% and EBIT margin 1.73% (EBIT $2.001M, EBITDA $3.027M). QoQ and YoY margin changes show deterioration—EBIT margin QoQ down ~88.72% and YoY down ~123.55%—driven by higher operating expenses and continued investment in R&D ($73.945M) and commercial expansion.

EPS actual -$0.02 versus estimate $0.02 produced an EPS surprise of -200%, reflecting continued GAAP losses at the per‑share level even as revenue grows. PE metrics remain non‑standard because of negative earnings (PE ratio -1,596.01), while forward EPS and forward PE remain negative, limiting valuation signals tied to earnings multiples.

Balance sheet and liquidity position provide visible support: cash and short‑term investments $880.211M, cash ratio 3.74 and current ratio 4.47 indicate strong near‑term coverage of liabilities (total current liabilities $235.198M). Total debt $434.959M produces debt‑to‑assets 38.86% and debt‑to‑EBITDA ~143.7, signaling leverage in relation to current earnings but manageable given the cash balance and operating runway assumptions implicit in the cash position.

Key valuation and ratio context: price‑to‑book 3.87 sits below the industry peer mean price‑to‑book 8.39 and median 6.33; enterprise multiple stands elevated at 389.29 while enterprise value $1.178B and EVR 10.16 reflect commercialization value embedded in market metrics. WMDST values the stock as under‑valued.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2026-06-30
REPORT DATE: 2026-08-06
NEXT REPORT DATE: 2026-11-05
CASH FLOW  Begin Period Cash Flow 452.7 M
 Operating Cash Flow 15.9 M
 Capital Expenditures -786.00 K
 Change In Working Capital 7.4 M
 Dividends Paid
 Cash Flow Delta 32.2 M
 End Period Cash Flow 484.9 M
 
INCOME STATEMENT REVENUE
 Total Revenue 115.9 M
 Forward Revenue 342.5 M
COSTS
 Cost Of Revenue 1.1 M
 Depreciation 1.0 M
 Depreciation and Amortization 1.0 M
 Research and Development 73.9 M
 Total Operating Expenses 118.9 M
PROFITABILITY
 Gross Profit 114.8 M
 EBITDA 3.0 M
 EBIT 2.0 M
 Operating Income -3.00 M
 Interest Income 3.6 M
 Interest Expense 2.5 M
 Net Interest Income 520.0 K
 Income Before Tax -514.00 K
 Tax Provision 294.0 K
 Tax Rate 40.0 %
 Net Income -808.00 K
 Net Income From Continuing Operations -808.00 K
EARNINGS
 EPS Estimate 0.02
 EPS Actual -0.02
 EPS Difference -0.04
 EPS Surprise -200.0 %
 Forward EPS -0.19
 
BALANCE SHEET ASSETS
 Total Assets 1.1 B
 Intangible Assets
 Net Tangible Assets 419.8 M
 Total Current Assets 1.1 B
 Cash and Short-Term Investments 880.2 M
 Cash 484.9 M
 Net Receivables 95.3 M
 Inventory 7.8 M
 Long-Term Investments 18.5 M
LIABILITIES
 Accounts Payable 26.3 M
 Short-Term Debt
 Total Current Liabilities 235.2 M
 Net Debt
 Total Debt 435.0 M
 Total Liabilities 699.6 M
EQUITY
 Total Equity 419.8 M
 Retained Earnings -819.11 M
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 8.25
 Shares Outstanding 50.866 M
 Revenue Per-Share 2.28
VALUATION
 Market Capitalization 1.6 B
 Enterprise Value 1.2 B
 Enterprise Multiple 389.293
Enterprise Multiple QoQ 474.895 %
Enterprise Multiple YoY -305.865 %
Enterprise Multiple IPRWA IMCR: 389.293
high: 148.972
median: 38.141
mean: 19.856
low: -178.99
 EV/R 10.165
CAPITAL STRUCTURE
 Asset To Equity 2.667
 Asset To Liability 1.6
 Debt To Capital 0.509
 Debt To Assets 0.389
Debt To Assets QoQ -4.385 %
Debt To Assets YoY -3.641 %
Debt To Assets IPRWA high: 0.833
IMCR: 0.389
mean: 0.281
median: 0.223
low: 0.0
 Debt To Equity 1.036
Debt To Equity QoQ -6.379 %
Debt To Equity YoY -7.779 %
Debt To Equity IPRWA high: 1.704
IMCR: 1.036
mean: 0.303
median: 0.098
low: -0.777
PRICE-BASED VALUATION
 Price To Book (P/B) 3.868
Price To Book QoQ -3.555 %
Price To Book YoY -9.29 %
Price To Book IPRWA high: 18.326
mean: 8.391
median: 6.334
IMCR: 3.868
low: -9.25
 Price To Earnings (P/E) -1596.012
Price To Earnings QoQ -1384.712 %
Price To Earnings YoY 860.89 %
Price To Earnings IPRWA high: 160.554
median: 40.973
mean: 20.564
low: -176.575
IMCR: -1596.012
 PE/G Ratio 14.778
 Price To Sales (P/S) 14.006
Price To Sales QoQ -5.361 %
Price To Sales YoY -17.166 %
Price To Sales IPRWA high: 559.892
mean: 54.716
median: 20.828
IMCR: 14.006
low: 0.983
FORWARD MULTIPLES
Forward P/E -172.923
Forward PE/G 1.601
Forward P/S 5.176
EFFICIENCY OPERATIONAL
 Operating Leverage -10.119
ASSET & SALES
 Asset Turnover Ratio 0.106
Asset Turnover Ratio QoQ 6.086 %
Asset Turnover Ratio YoY 13.96 %
Asset Turnover Ratio IPRWA high: 0.511
mean: 0.116
IMCR: 0.106
median: 0.105
low: 0.0
 Receivables Turnover 1.314
Receivables Turnover Ratio QoQ -4.495 %
Receivables Turnover Ratio YoY -10.885 %
Receivables Turnover Ratio IPRWA high: 4.472
median: 1.538
mean: 1.444
IMCR: 1.314
low: 0.058
 Inventory Turnover 0.136
Inventory Turnover Ratio QoQ 134.289 %
Inventory Turnover Ratio YoY -20.058 %
Inventory Turnover Ratio IPRWA high: 2.707
mean: 0.492
median: 0.453
IMCR: 0.136
low: 0.029
 Days Sales Outstanding (DSO) 69.432
CASH CYCLE
 Cash Conversion Cycle Days (CCC) -4181.052
Cash Conversion Cycle Days QoQ 595.841 %
Cash Conversion Cycle Days YoY 92.43 %
Cash Conversion Cycle Days IPRWA high: 1415.294
median: 197.717
mean: 179.216
low: -771.823
IMCR: -4181.052
CAPITAL DEPLOYMENT
 Cash Conversion Ratio 0.142
 CapEx To Revenue -0.007
 CapEx To Depreciation -0.766
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 814.0 M
 Net Invested Capital 814.0 M
 Invested Capital 814.0 M
 Net Tangible Assets 419.8 M
 Net Working Capital 815.8 M
LIQUIDITY
 Cash Ratio 3.742
 Current Ratio 4.469
Current Ratio QoQ 6.894 %
Current Ratio YoY -24.171 %
Current Ratio IPRWA high: 31.351
mean: 4.801
IMCR: 4.469
median: 3.163
low: 0.34
 Quick Ratio 4.436
Quick Ratio QoQ 6.981 %
Quick Ratio YoY -24.321 %
Quick Ratio IPRWA high: 16.477
IMCR: 4.436
mean: 2.803
median: 2.737
low: 0.811
COVERAGE & LEVERAGE
 Debt To EBITDA 143.693
 Cost Of Debt 0.347 %
 Interest Coverage Ratio 0.796
Interest Coverage Ratio QoQ -85.129 %
Interest Coverage Ratio YoY -127.873 %
Interest Coverage Ratio IPRWA high: 533.0
mean: 42.233
median: 2.337
IMCR: 0.796
low: -1501.103
 Operating Cash Flow Ratio -0.074
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO) 5937.137
DIVIDENDS
 Dividend Coverage Ratio
 Dividend Payout Ratio
 Dividend Rate
 Dividend Yield
PERFORMANCE GROWTH
 Asset Growth Rate 4.414 %
 Revenue Growth 8.671 %
Revenue Growth QoQ 311.924 %
Revenue Growth YoY 99.379 %
Revenue Growth IPRWA high: 278.717 %
mean: 15.349 %
median: 11.617 %
IMCR: 8.671 %
low: -242.388 %
 Earnings Growth -108.0 %
Earnings Growth QoQ -23.765 %
Earnings Growth YoY -64.0 %
Earnings Growth IPRWA high: 185.714 %
median: 13.636 %
mean: 12.799 %
IMCR: -108.0 %
low: -155.294 %
MARGINS
 Gross Margin 99.061 %
Gross Margin QoQ -0.534 %
Gross Margin YoY 0.124 %
Gross Margin IPRWA high: 100.0 %
IMCR: 99.061 %
median: 79.764 %
mean: 78.086 %
low: -3.536 %
 EBIT Margin 1.726 %
EBIT Margin QoQ -88.72 %
EBIT Margin YoY -123.553 %
EBIT Margin IPRWA high: 103.704 %
median: 22.839 %
IMCR: 1.726 %
mean: -92.864 %
low: -3750.867 %
 Return On Sales (ROS) -2.584 %
Return On Sales QoQ -137.866 %
Return On Sales YoY -82.982 %
Return On Sales IPRWA high: 74.372 %
median: 30.748 %
IMCR: -2.584 %
mean: -75.531 %
low: -3837.989 %
CASH FLOW
 Free Cash Flow (FCF) 15.1 M
 Free Cash Flow Yield 0.933 %
Free Cash Flow Yield QoQ -194.721 %
Free Cash Flow Yield YoY -39.533 %
Free Cash Flow Yield IPRWA high: 13.067 %
IMCR: 0.933 %
median: 0.852 %
mean: 0.544 %
low: -26.527 %
 Free Cash Growth -197.339 %
Free Cash Growth QoQ 250.993 %
Free Cash Growth YoY -101.064 %
Free Cash Growth IPRWA high: 175.34 %
mean: 20.583 %
median: 1.424 %
IMCR: -197.339 %
low: -249.171 %
 Free Cash To Net Income -18.74
 Cash Flow Margin -15.044 %
 Cash Flow To Earnings 21.584
VALUE & RETURNS
 Economic Value Added 0.03
 Return On Assets (ROA) -0.074 %
Return On Assets QoQ -106.101 %
Return On Assets YoY -92.418 %
Return On Assets IPRWA high: 20.575 %
median: 0.317 %
IMCR: -0.074 %
mean: -4.032 %
low: -44.847 %
 Return On Capital Employed (ROCE) 0.226 %
 Return On Equity (ROE) -0.002
Return On Equity QoQ -105.827 %
Return On Equity YoY -92.757 %
Return On Equity IPRWA high: 0.462
median: 0.006
IMCR: -0.002
mean: -0.104
low: -0.887
 DuPont ROE -0.199 %
 Return On Invested Capital (ROIC) 0.147 %
Return On Invested Capital QoQ -92.744 %
Return On Invested Capital YoY -120.22 %
Return On Invested Capital IPRWA high: 30.797 %
median: 3.876 %
IMCR: 0.147 %
mean: -0.275 %
low: -27.378 %

Six-Week Outlook

Technical momentum favors further gains: MACD above signal, rising RSI below overbought, ADX indicating a strong trend, and price above key moving averages. Watch for confirmation via increased volume and maintenance of price above the 20‑day average $35.54 and the super trend lower support at $34.01. The MRO positive reading signals elevated risk of a corrective pullback; traders should monitor any MACD peak‑and‑reverse or DI+ peak‑and‑reverse as a shift from the current bullish momentum. Near‑term target cluster sits between the price‑target mean $39.60 and the 52‑week high $40.72, with initial technical support near the super trend lower and the 50‑day average $33.40.

About Immunocore Holdings plc

Immunocore Holdings plc (NASDAQ:IMCR) develops innovative immunotherapies aimed at treating cancer, infectious diseases, and autoimmune conditions. Based in Abingdon, UK, the company advances its proprietary ImmTAC technology platform to harness the body’s immune system in combating diseases. Immunocore’s leading product, KIMMTRAK, targets unresectable or metastatic uveal melanoma, offering a novel treatment option for patients. The company’s pipeline includes tebentafusp, currently progressing through Phase 2/3 trials for advanced cutaneous melanoma. Additionally, Immunocore evaluates IMC-F106C in Phase 3 trials for first-line advanced cutaneous melanoma and in Phase 1/2 trials for a range of tumors, such as ovarian and lung cancers. The company also explores therapies for colorectal, gastrointestinal, and viral infections with candidates like IMC-R117C and IMC-M113V. Committed to addressing unmet medical needs, Immunocore conducts preclinical trials targeting solid tumor cancers and type 1 diabetes. Founded in 1999, Immunocore leverages its expertise to deliver transformative therapies, aiming to improve patient outcomes across the globe.



© 2026 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.